NeoPharm CO., LTD. (KOSDAQ:092730)

Market Cap	306.73B +74.4%
Revenue (ttm)	129.81B +15.7%
Net Income	27.80B +24.5%
EPS	1,777.18 +24.5%
Shares Out	15.64M
PE Ratio	11.03
Forward PE	9.58
Dividend	750.00 (3.82%)
Ex-Dividend Date	Dec 29, 2025

Volume	62,509
Average Volume	101,196
Open	20,200
Previous Close	20,750
Day's Range	18,700 - 20,200
52-Week Range	11,300 - 22,650
Beta	0.54
RSI	55.30
Earnings Date	Feb 6, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2024, NeoPharm CO., LTD.'s revenue was 119.01 billion, an increase of 22.56% compared to the previous year's 97.10 billion. Earnings were 23.06 billion, a decrease of -0.64%.